Displaying Tetra‐Membrane Spanning Claudins on Enveloped Virus‐Like Particles for Cancer Immunotherapy

Schneider, Irene C.; Hartmann, Jessica; Braun, Gundula; Stitz, Jörn; Klamp, Thorsten; Bihi, Mahjoub; Şahin, Uğur; Buchholz, Christian J.

doi:10.1002/biot.201700345

Cited by 13 publications

(7 citation statements)

References 31 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incorporation of heterologous viral glycoproteins but also non-viral transmembrane proteins into LV particles expressed in the producer cell line has been described before 20, 23, 24. For envelope proteins derived from viruses, such as MV or NiV, cytoplasmic tail truncations have to be performed to allow efficient incorporation into LV particles 25, 26.…”

Section: Discussionmentioning

confidence: 99%

Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors

Jamali

Kapitza

Schaser

et al. 2019

Molecular Therapy - Methods & Clinical Development

Self Cite

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR)-modified T cells have revealed promising results in the treatment of cancer, but they still need to overcome various hurdles, including a complicated manufacturing process. Receptor-targeted lentiviral vectors (LVs) delivering genes selectively to T cell subtypes may facilitate and improve CAR T cell generation, but so far they have resulted in lower gene delivery rates than conventional LVs (vesicular stomatitis virus [VSV]-LV). To overcome this limitation, we studied the effect of the transduction enhancer Vectofusin-1 on gene delivery to human T cells with CD4-and CD8-targeted LVs, respectively, encoding a second-generation CD19-CAR in conjunction with a truncated version of the low-affinity nerve growth factor receptor (DLNGFR) as reporter. Vectofusin-1 significantly enhanced the gene delivery of CD4-and CD8-LVs without a loss in target cell selectivity and killing capability of the generated CAR T cells. Notably, delivery rates mediated by VSV-LV were substantially reduced by Vectofusin-1. Interestingly, a transient off-target signal in samples treated with Vectofusin-1 was observed early after transduction. However, this effect was not caused by uptake and expression of the transgene in off-target cells, but rather it resulted from cell-bound LV particles having DLNGFR incorporated into their surface. The data demonstrate that gene transfer rates in the range of those mediated by VSV-LVs can be achieved with receptor-targeted LVs.

show abstract

Section: Discussionmentioning

confidence: 99%

Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors

Jamali

Kapitza

Schaser

et al. 2019

Molecular Therapy - Methods & Clinical Development

Self Cite

View full text Add to dashboard Cite

show abstract

“…CLDN6 is a surface antigen of carcinoembryonic cells and has an ideal expression profile for CAR-T cells. Although some research conclusions are inconsistent on this topic, study results show that CLDN6 LPX can cause CLDN6-CAR-T proliferation and survival effectively in vivo , allowing CAR-T cells to treat solid tumours ( 73 ). This provides a new strategy for the treatment of solid tumours using CAR-T cells.…”

Section: Prospect Of Cldn6 In the Treatment Of Tumoursmentioning

confidence: 99%

Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review)

Yang

Fan

et al. 2021

Mol Med Rep

View full text Add to dashboard Cite

Tight junctions (TJs) are an important component of cell connectivity; they maintain cell polarity, permeability and adhesion, and participate in the regulation of cell proliferation and differentiation. The claudin (cldn) family is integral to TJs, and cldn6 is an important member of this family. abnormal expression of cldn6 can destroy the integrity of TJs through various mechanisms and can serve multiple roles in the occurrence and development of tumours. cldn6 is widely expressed in various tumours but rarely expressed in healthy adult tissues. The aim of this review is to critically examine the recent literature on cldn6, including its structure, expression in different tumours, regulatory mechanisms and therapeutic prospects. although some conclusions are controversial, in certain tumours, such as liver, ovarian, endometrial and oesophageal cancer, and atypical teratoid/rhabdoid tumours, research consistently shows that cldn6 is expressed in tumour tissues but is not expressed or is expressed at low levels in surrounding tissues. in these tumours, cldn6 has potential as a carcinoembryonic antigen and a therapeutic target. Contents1. introduction 2. Structural characteristics of cldn6 3. expression and regulation mechanisms of cldn6 in tumours 4. cldn6 and drug resistance in cancer 5. Prospect of cldn6 in the treatment of tumours 6. discussion conclusionHuan du 1,2 , XiYue YanG 2 , JinJia Fan 2 and XiaoBo du 1

show abstract

“…Schneider et al [ 169 ] displayed tumor-associated antigens on the surface of VLP originated from murine leukemia virus. VLP displayed with the tumor-associated antigens triggered a powerful immune response due to the immunogenicity of VLP itself and effectively treated the tumor, showing the potential of VLP as a tumor vaccine.…”

Section: Cancer Therapy By Using Protein Nanoparticlesmentioning

confidence: 99%

Protein nanoparticles directed cancer imaging and therapy

Miao

Yang

et al. 2022

Nano Convergence

View full text Add to dashboard Cite

Cancer has been a serious threat to human health. Among drug delivery carriers, protein nanoparticles are unique because of their mild and environmentally friendly preparation methods. They also inherit desired characteristics from natural proteins, such as biocompatibility and biodegradability. Therefore, they have solved some problems inherent to inorganic nanocarriers such as poor biocompatibility. Also, the surface groups and cavity of protein nanoparticles allow for easy surface modification and drug loading. Besides, protein nanoparticles can be combined with inorganic nanoparticles or contrast agents to form multifunctional theranostic platforms. This review introduces representative protein nanoparticles applicable in cancer theranostics, including virus-like particles, albumin nanoparticles, silk protein nanoparticles, and ferritin nanoparticles. It also describes the common methods for preparing them. It then critically analyzes the use of a variety of protein nanoparticles in improved cancer imaging and therapy.

show abstract

Displaying Tetra‐Membrane Spanning Claudins on Enveloped Virus‐Like Particles for Cancer Immunotherapy

Cited by 13 publications

References 31 publications

Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors

Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors

Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review)

Protein nanoparticles directed cancer imaging and therapy

Contact Info

Product

Resources

About